Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma

Cancer

Volumn 86, Issue 3, 1999, Pages 470-476

  Falcone, Alfredo ^a   Antonuzzo, Andrea ^a   Danesi, Romano ^a,b   Allegrini, Giacomo ^a   Monica, Lencioni ^a   Pfanner, Elisabetta ^a   Masi, Gianluca ^a   Ricci, Sergio ^a   Del Tacca, Mario ^a   Conte, Pierfranco ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Epirubicin; Hormone refractory; Prostate carcinoma; Suramin

Indexed keywords

ANTIANDROGEN; CORTISONE ACETATE; CYTOTOXIC AGENT; EPIRUBICIN; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BAYES THEOREM; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURAMIN;

EID: 0033178459     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990801)86:3<470::AID-CNCR15>3.0.CO;2-7     Document Type: Article

References (31)

1. Vogelzang NJ. Hormone-refractory prostate cancer: an emerging epidemic. Semin Oncol 1996;23(Suppl):1-62.
2. Voogd TE, Vansterkenburg ELM, Wilting J, Janssen LHM. Recent research on the biological activity of suramin. Pharmacol Rev 1993;45:177-203.
3. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, et al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantonic membrane. Br J Cancer 1993;68:932-8.
4. Taylor CW, Lui R, Fanta P, Salmon SE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 1992;84:489-94.
5. Falcone A, Danesi R, Zaccaro L, Pieracci D, Pfanner E, Cianci C, et al. Synergistic antiproliferative activity of suramin and a2a-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. Eur J Cancer 1993;30A:516-20.
6. Falcone A, Pfanner E, Cianci C, Danesi R, Brunetti I, Del Tacca M, et al. Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. Cancer 1995;75:440-3.
7. Stein CA, La Rocca RV, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499-508.
8. Myers C, Cooper M, Stein C, La Rocca R, Walther M, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-9.
9. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Thaczuk KH, Sridhara R, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993;85:611-21.
10. Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13:2174-86.
11. Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, et al. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 1995;13:2214-22.
12. Clark JW, Chabner BA. Suramin and prostate cancer: where do we go from here? J Clin Oncol 1995;13:2155-7.
13. Delaere KP, Leliefeld H, Peulen F, Stapper EW, Smeets J, Wils J. Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma. Br J Urol 1992;70:641-2.
14. Newling DW. The use of adriamycin and its derivatives in the treatment of prostatic cancer. Cancer Chemother Pharmacol 1992;30(Suppl):90-4.
15. Brausi M, Jones WG, Fossa SD, de Mudler PH, Droz JP, Lentz MA, et al. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer 1995;31A:1622-66.
16. Neri B, Barbagli G, Bellesi P, Di Loro R, Lombardi V, Lombardo C, et al. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer. Anticancer Res 1997; 17:3817-20.
17. Fruehauf JP, Myers CE, Sinha BK. Synergistic activity of suramin with tumor necrosis factor a and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 1990;82: 1206-9.
18. Tu SM, McKonnel K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, et al. Combination of adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 1995;93:147-55.
19. Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, et al. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 1992;52:64-70.
20. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Kelly KW, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa S. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-15.
22. Smith DC, Dunn RL, Strawderman MS, Pienta K. Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835-43.
23. Supko JG, Malspeis L. A rapid isocratic HPLC assay of suramin in human plasma. J Liquid Chromatogr 1990;116: 121-31.
24. Kelly KW, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13:2208-13.
25. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995;76:453-62.
26. Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, et al. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 1998;4:37-44.
27. Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995;13:2187-95.
28. Hudes GR, Greenberg R, Krigel RL. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10:1754-61.
29. Pienta KJ, Redman B, Hussain M. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 10:2005-12.
30. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, et al. Phase II study of oral etoposide and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997;20:383-6.
31. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156-63.